Cabaletta Bio (NASDAQ:CABA) Given New $25.00 Price Target at HC Wainwright

Cabaletta Bio (NASDAQ:CABA) had its target price trimmed by HC Wainwright from $30.00 to $25.00 in a research note issued to investors on Friday, Benzinga reports. The firm currently has a buy rating on the stock.

A number of other analysts have also recently commented on the company. Stifel Nicolaus restated a buy rating and issued a $32.00 price objective on shares of Cabaletta Bio in a research report on Monday, June 17th. Cantor Fitzgerald reiterated an overweight rating and issued a $50.00 price objective on shares of Cabaletta Bio in a report on Friday, June 21st. Nine equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of Buy and a consensus price target of $33.89.

Cabaletta Bio Price Performance

CABA traded up $0.15 during trading on Friday, reaching $4.16. 3,036,164 shares of the company’s stock were exchanged, compared to its average volume of 1,141,895. The company’s fifty day simple moving average is $8.04 and its 200-day simple moving average is $14.18. The stock has a market capitalization of $200.83 million, a P/E ratio of -2.43 and a beta of 2.42. Cabaletta Bio has a 1 year low of $3.47 and a 1 year high of $26.35.

Cabaletta Bio (NASDAQ:CABA) last posted its earnings results on Thursday, August 8th. The company reported ($0.56) EPS for the quarter, missing the consensus estimate of ($0.55) by ($0.01). Equities analysts forecast that Cabaletta Bio will post -2.07 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of CABA. Macroview Investment Management LLC acquired a new position in shares of Cabaletta Bio during the fourth quarter worth about $26,000. Tower Research Capital LLC TRC boosted its holdings in Cabaletta Bio by 65.9% during the fourth quarter. Tower Research Capital LLC TRC now owns 2,623 shares of the company’s stock worth $60,000 after buying an additional 1,042 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Cabaletta Bio by 65.4% during the first quarter. China Universal Asset Management Co. Ltd. now owns 8,206 shares of the company’s stock worth $140,000 after buying an additional 3,244 shares during the period. EntryPoint Capital LLC purchased a new position in Cabaletta Bio in the first quarter valued at about $147,000. Finally, Bayesian Capital Management LP acquired a new stake in shares of Cabaletta Bio during the 1st quarter valued at approximately $191,000.

About Cabaletta Bio

Cabaletta Bio, Inc, a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis.